Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer

Breast cancer (BC) remains a leading cause of cancer-related mortality among women, with hormone-receptor-positive subtypes frequently developing resistance to standard therapies. Nudix hydrolase 5 (NUDT5), an enzyme integral to ADP-ribose metabolism, DNA repair, and hormone-driven transcription, ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Majed S. AlFayi, Mohd Saeed, Irfan Ahmad, Mohd Adnan Kausar, Samra Siddiqui, Saba Irem, Faisal Fawaz Alshammari, Riadh Badraoui, Dharmendra Kumar Yadav
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Chemical Physics Impact
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667022425000593
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849694400279478272
author Majed S. AlFayi
Mohd Saeed
Irfan Ahmad
Mohd Adnan Kausar
Samra Siddiqui
Saba Irem
Faisal Fawaz Alshammari
Riadh Badraoui
Dharmendra Kumar Yadav
author_facet Majed S. AlFayi
Mohd Saeed
Irfan Ahmad
Mohd Adnan Kausar
Samra Siddiqui
Saba Irem
Faisal Fawaz Alshammari
Riadh Badraoui
Dharmendra Kumar Yadav
author_sort Majed S. AlFayi
collection DOAJ
description Breast cancer (BC) remains a leading cause of cancer-related mortality among women, with hormone-receptor-positive subtypes frequently developing resistance to standard therapies. Nudix hydrolase 5 (NUDT5), an enzyme integral to ADP-ribose metabolism, DNA repair, and hormone-driven transcription, has emerged as a promising therapeutic target. This study employed computational drug discovery approaches to identify potential NUDT5 inhibitors from FDA-approved compounds in the Drug-Lib database. Virtual screening and molecular docking revealed four promising candidates: Afacifenacin, Penfluridol, Belaperidone, and BMS-754,807. Detailed molecular dynamics simulations validated their stability, with trajectory analyses, including RMSD, RMSF, and PCA-based free energy landscapes, highlighting consistent and favourable interactions. Among these, BMS-754,807 demonstrated the strongest inhibitory potential, with stable binding, superior hydrogen bonding interactions, and the lowest free energy values. These findings emphasize the therapeutic promise of these compounds, particularly BMS-754,807, in targeting hormone-resistant breast cancer. Future in vitro and in vivo studies will be crucial to confirm these results and advance these inhibitors toward clinical applications.
format Article
id doaj-art-cf104efd019548bfa0fe07d4aa686ff8
institution DOAJ
issn 2667-0224
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series Chemical Physics Impact
spelling doaj-art-cf104efd019548bfa0fe07d4aa686ff82025-08-20T03:20:05ZengElsevierChemical Physics Impact2667-02242025-06-011010087110.1016/j.chphi.2025.100871Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancerMajed S. AlFayi0Mohd Saeed1Irfan Ahmad2Mohd Adnan Kausar3Samra Siddiqui4Saba Irem5Faisal Fawaz Alshammari6Riadh Badraoui7Dharmendra Kumar Yadav8Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi ArabiaDepartment of Biology, College of Science, University of Hail, Hail Saudi ArabiaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia; Corresponding authors.Department of Biochemistry, College of Medicine, University of Hail, Hail Saudi ArabiaDepartment Health Services Management, College of Public Health and Health Informatics, University of Hail, Hail, Saudi ArabiaSchool of nursing sciences & Allied health, Jamia Hamdard, New DelhiCollege of Medicine, University of Hail, Hail Saudi ArabiaDepartment of Biology, College of Science, University of Hail, Hail Saudi ArabiaDepartment of Biologics, College of Pharmacy, Gachon University, Hambakmoeiro, Yeonsugu, Incheon City 21924, South Korea; Corresponding authors.Breast cancer (BC) remains a leading cause of cancer-related mortality among women, with hormone-receptor-positive subtypes frequently developing resistance to standard therapies. Nudix hydrolase 5 (NUDT5), an enzyme integral to ADP-ribose metabolism, DNA repair, and hormone-driven transcription, has emerged as a promising therapeutic target. This study employed computational drug discovery approaches to identify potential NUDT5 inhibitors from FDA-approved compounds in the Drug-Lib database. Virtual screening and molecular docking revealed four promising candidates: Afacifenacin, Penfluridol, Belaperidone, and BMS-754,807. Detailed molecular dynamics simulations validated their stability, with trajectory analyses, including RMSD, RMSF, and PCA-based free energy landscapes, highlighting consistent and favourable interactions. Among these, BMS-754,807 demonstrated the strongest inhibitory potential, with stable binding, superior hydrogen bonding interactions, and the lowest free energy values. These findings emphasize the therapeutic promise of these compounds, particularly BMS-754,807, in targeting hormone-resistant breast cancer. Future in vitro and in vivo studies will be crucial to confirm these results and advance these inhibitors toward clinical applications.http://www.sciencedirect.com/science/article/pii/S2667022425000593Breast CancerNUDT5MD simulationPCAFEL
spellingShingle Majed S. AlFayi
Mohd Saeed
Irfan Ahmad
Mohd Adnan Kausar
Samra Siddiqui
Saba Irem
Faisal Fawaz Alshammari
Riadh Badraoui
Dharmendra Kumar Yadav
Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
Chemical Physics Impact
Breast Cancer
NUDT5
MD simulation
PCA
FEL
title Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
title_full Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
title_fullStr Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
title_full_unstemmed Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
title_short Unveiling the therapeutic role of penfluridol and BMS-754,807: NUDT5 inhibition in breast cancer
title_sort unveiling the therapeutic role of penfluridol and bms 754 807 nudt5 inhibition in breast cancer
topic Breast Cancer
NUDT5
MD simulation
PCA
FEL
url http://www.sciencedirect.com/science/article/pii/S2667022425000593
work_keys_str_mv AT majedsalfayi unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT mohdsaeed unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT irfanahmad unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT mohdadnankausar unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT samrasiddiqui unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT sabairem unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT faisalfawazalshammari unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT riadhbadraoui unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer
AT dharmendrakumaryadav unveilingthetherapeuticroleofpenfluridolandbms754807nudt5inhibitioninbreastcancer